In support of our data, a recent study of a cohort of non-small cell lung carcinoma patients demonstrated that PD-L1 expression was shown in 25% and 31% of tumors in the discovery and validation cohorts, respectively, whereas B7-H7 expression was observed in 61% and 64% of tumors, respectively. Here, CD80 is linked to non-small cell lung carcinoma.